A Multicenter Phase 3 Trial of Biotherapy Using Cryopreserved Human Umbilical Cord (TTAX01) for Late Stage, Complex Non-healing Diabetic Foot Ulcers (AMBULATE DFU)

Who is this study for? Patients with late stage, complex non-healing diabetic foot ulcers
What treatments are being studied? TTAX01
Status: Completed
Location: See all (16) locations...
Intervention Type: Biological, Other
Study Type: Interventional
Study Phase: Phase 3
SUMMARY

It is hypothesized that application at 4-week or greater intervals of the human placental umbilical cord tissue TTAX01 to the surface of a well debrided, complex diabetic foot ulcer (DFU) will, with concomitant management of infection, will result in a higher rate of wounds showing complete healing within 26 weeks of initiating therapy, compared with standard care alone. This confirmatory Phase 3 study examines a population of diabetic foot ulcer patients having adequate perfusion, with or without neuropathy, and a high suspicion of associated osteomyelitis in a complex, high grade wound.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• The subject has signed the informed consent form

• The subject is male or female, at least 18 years of age inclusive at the date of Screening

• The subject has confirmed diagnosis of Type I or Type II diabetes

• The subject's index ulcer is located on the plantar surface, inter digital, heel, lateral or medial surface of the foot

• The subject has an index ulcer with visible margins having an area ≤ 12.0 cm2 when measured by the electronic measuring device at Screening

• The subject's index ulcer extends beyond the dermis, into subcutaneous tissue with evidence of exposed bone, tendon, muscle and/or joint capsule

• The subject presents with history, signs or symptoms leading to a clinical suspicion of osteomyelitis in the opinion of the Investigator supported by positive Probe to Bone (PTB) and any of the following: radiographic (X-ray, Magnetic Resonance Imaging (MRI), or bone scan) or evidence of bone necrosis

• The subject has an ABI ≥ 0.7 to ≤ 1.3 or TcPO2 ≥ 40 mmHg on the dorsum of the affected foot, or Great Toe Pressure ≥ 50 mmHg

• The subject is under the care of a physician for the management of Diabetes Mellitus

• The subject is willing to return for all mandatory visits as defined in the protocol

• The subject is willing to follow the instructions of the trial Investigator

Locations
United States
California
Center for Clinical Research, Inc
San Francisco
UCLA Olive View
Sylmar
Florida
University of Miami
Miami
Paley Orthopedic & Spine Institute
West Palm Beach
Illinois
Rosalind Franklin University
North Chicago
Louisiana
Ochsner Medical Center
New Orleans
North Carolina
University of North Carolina
Chapel Hill
New York
Mount Sinai West
New York
Ohio
University Hospitals Richmond Medical Center
Richmond Heights
Oregon
Oregon Health & Science University
Portland
Tennessee
Vanderbilt University Medical Center
Nashville
Texas
JPS
Fort Worth
Futuro Clinical Trials, LLC
Mcallen
Bio-X-Cell Research
San Antonio
Utah
Foot & Ankle Institute
St. George
Virginia
Carilion Clinic
Roanoke
Time Frame
Start Date: 2020-07-01
Completion Date: 2024-06-12
Participants
Target number of participants: 220
Treatments
Experimental: TTAX01
TTAX01 plus standard care
Other: Control
Standard Care alone
Related Therapeutic Areas
Sponsors
Leads: BioTissue Holdings, Inc

This content was sourced from clinicaltrials.gov